Velcade in MALT Lymphoma Patients
Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|
- to evaluate the clinical potential of bortezomib
- to induce objective/histologic responses in patients with MALT-Lymphoma
- to evaluate the impact of bortezomib on progression free survival
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.
It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00373906
|Principal Investigator:||Markus Raderer, Prof||Department of Internal Medicine I|